EYPT
EyePoint Pharmaceuticals, Inc.
There isn't enough reported data to score EYPT yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
EYPT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
EYPT's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
EYPT PE Valuation
EYPT has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
EYPT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Moderate | |
| Low |
Analysts expect EYPT's losses to shrink, with revenue declining. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
EYPT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.97 | -$0.97 |
| Q2 2026 | -$3.75 | -$1.06 |
| Q1 2026 | -$3.51 | -$1.09 |
| Q4 2025 | -$3.17 | -$0.85 |
| Q3 2025 | -$3.00 | -$1.01 |
| Q2 2025 | -$2.69 | -$0.91 |
| Q1 2025 | -$2.42 | -$0.61 |
| Q4 2024 | -$2.32 | -$0.50 |
EYPT is still losing money, but less than at its worst: $3.97 per share over the past year, against $5.60 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over EYPT on earnings quality, reporting a profit while its opponent remains loss making.
EYPT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $756K | -22% |
| Q2 2026 | $507K | -90% |
| Q1 2026 | $696K | -97% |
| Q4 2025 | $620K | -95% |
| Q3 2025 | $966K | -91% |
| Q2 2025 | $5.3M | -44% |
| Q1 2025 | $24.5M | +109% |
| Q4 2024 | $11.6M | -17% |
EYPT's revenue has slid since its 2025 peak: $756,000 last quarter, down 22% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -12814% | -6394 points |
| Q2 2026 | -19207% | -18040 points |
| Q1 2026 | -12532% | -12333 points |
| Q4 2025 | -11346% | -10956 points |
| Q3 2025 | -6421% | -6110 points |
| Q2 2025 | -1167% | -802 points |
| Q1 2025 | -200% | +86 points |
| Q4 2024 | -390% | -274 points |
EYPT's operating margin was −12814% last quarter, down 6394 points from the same quarter a year ago, near the bottom of its range since 2019.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over EYPT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over EYPT on profitability, with a higher operating margin.
EYPT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | -$27.9M |
| Q2 2026 | -$63.5M | +$261K |
| Q1 2026 | -$81.5M | -$28.2M |
| Q4 2025 | -$66M | -$29.8M |
| Q3 2025 | -$60.2M | -$19.6M |
| Q2 2025 | -$63.8M | -$42.7M |
| Q1 2025 | -$53.4M | -$21M |
| Q4 2024 | -$36.2M | -$12.2M |
EYPT has burned cash in almost every quarter: −$299M over the past year, against −$214M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over EYPT on cash generation, producing positive trailing cash flow while its opponent burns cash.
EYPT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +28% | +15.3M shares |
| 1 year | +86% | +32.2M shares |
| 3 years | +143% | +41M shares |
EYPT has 70M diluted shares, up 86% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over EYPT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
EYPT Net Leverage
EYPT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
EYPT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 22.9 | Oversold |
| Stochastic | 0.1 | Oversold |
EYPT's weekly RSI is 23 (oversold) and its Stochastic is 0 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
EYPT PE vs Healthcare Sector
EYPT has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
EYPT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.84 | 83% below |
| 20 week MA | $6.61 | 95% below |
| 50 week MA | $11.3 | 97% below |
| 100 week MA | $10.3 | 97% below |
| 200 week MA | $10.8 | 97% below |
EYPT is in a downtrend: it's below all five of its weekly moving averages, and 97% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over EYPT on trend strength, trading above more of its moving averages.
EYPT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $15.0 | $4.99 | -67% |
| 2021 | $4.99 | $13.6 | +172% |
| 2022 | $13.6 | $2.89 | -79% |
| 2023 | $2.89 | $23.1 | +700% |
| 2024 | $23.1 | $7.20 | -69% |
| 2025 | $7.20 | $18.3 | +154% |
| 2026 YTD | $18.3 | $0.32 | -98% |
EYPT's yearly returns have swung widely, from +700% in 2023 to −79% in 2022. It's down 98% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over EYPT on returns for 2026, with the stronger performance.